Volume | 833,232 |
|
|||||
News | - | ||||||
Day High | 0.7243 | Low High |
|||||
Day Low | 0.6664 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Atara Biotherapeutics Inc | ATRA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.6884 | 0.6664 | 0.7243 | 0.7186 | 0.6974 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
3,238 | 833,232 | US$ 0.7097166 | US$ 591,359 | - | 0.1986 - 3.015 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:02:55 | 7 | US$ 0.7092 | USD |
Atara Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
73.38M | 101.92M | - | 8.57M | -276.13M | -2.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atara Biotherapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATRA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.68 | 0.7401 | 0.6401 | 0.6847534 | 1,022,813 | 0.0386 | 5.68% |
1 Month | 0.67 | 0.8325 | 0.6194 | 0.7135842 | 1,133,009 | 0.0486 | 7.25% |
3 Months | 0.6015 | 1.58 | 0.5686 | 0.9016943 | 2,819,044 | 0.1171 | 19.47% |
6 Months | 1.42 | 1.58 | 0.1986 | 0.632553 | 3,934,708 | -0.7014 | -49.39% |
1 Year | 3.00 | 3.015 | 0.1986 | 0.9867575 | 2,738,194 | -2.28 | -76.05% |
3 Years | 14.33 | 20.04 | 0.1986 | 4.22 | 1,740,010 | -13.61 | -94.99% |
5 Years | 31.68 | 36.55 | 0.1986 | 6.94 | 1,376,711 | -30.96 | -97.73% |
Atara Biotherapeutics Description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs. |